Company Profiles

driven by the PitchBook Platform

EndoStim

EndoStim
2009 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$12.1M LATEST DEAL AMOUNT
16 INVESTORS
Description

Developer of microstimulator technology designed to treat sphincter-related disorders. The company's microstimulator technology provides long-term reflux control by restoring normal esophageal function, directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus, often the underlying cause of reflux, enabling patients with gastroesophageal reflux disease (GERD) to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Surgical Devices
Primary Office
  • 4101 McEwen
  • Suite 336
  • Dallas, TX 75244
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore EndoStim’s full profile, request a free trial.

EndoStim Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 12-Jan-2018 $12.1M 0000 000.00 Completed Generating Revenue
7. Later Stage VC (Series D) 01-Mar-2016 0000 000.00 000.00 Completed Generating Revenue
6. IPO 09-Dec-2015 000.00 000.00 Cancelled Generating Revenue
5. Later Stage VC (Series C1) 01-May-2015 00.000 0000 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 29-May-2013 000.00 000.00 000.00 Completed Startup
3. Early Stage VC (Series B1) 01-Nov-2011 00.000 0000 0000 Completed Startup
2. Early Stage VC (Series B) 13-Jul-2010 $6M $7.5M 000.00 Completed Startup
1. Early Stage VC (Series A) 30-Sep-2009 $1.5M $1.5M 000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

EndoStim Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D3 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D2 0 00.000000 00 00 00 00 00 00
Series D1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C1 000,000 00.000000 00 000 000 00 00.00 0.00
Series C 000,000 00.000000 00 000.00 000.00 00 00.00 0.000
Series B1 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 1,119,317 $0.001000 8% $5 $5 1x $3.13 5.96%
Series A 195,452 $0.001000 8% $3.33 $3.33 1x $2.63 0.82%
To view this company’s complete Cap Table, request access »

EndoStim Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Endeavour Vision Venture Capital Minority 000 0000 000000 0
Gimv PE/Buyout Minority 000 0000 000000 0
Prettybrook Partners PE/Buyout Majority 000 0000 000000 0
Wellington Partners Venture Capital Minority 000 0000 000000 0
Healthios Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

EndoStim Executive Team (13)

Name Title Board
Seat
Contact
Info
Rohan Hoare Ph.D President, Board Member & Chief Executive Officer
Kimberly Pinson Chief Financial Officer & Assistant Secretary
Bevil Hogg Co-Founder & Consultant
Ofer Glasberg Director, Surgery and Physicians Education
Raul Perez MD Co-Founder & Board Member

5 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

EndoStim Board Members (7)

Name Representing Role Since Contact
Info
Alexander Schmitz Endeavour Vision Board Member 000 0000
Douglas French Santé Ventures Chairman 000 0000
Fred Goad Jr. Voyent Partners Board Member 000 0000
Jeffrey McDonnell Self Board Member 000 0000
Ralph Dacey MD Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »